Drugs / Entospletinib
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03135028 | May 2017 → Feb 2019 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT02521376 | Nov 2015 → Oct 2017 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02457598 | Jun 2015 → Sep 2024 | B-cell neoplasm | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT01841489 | May → Aug 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03225924 | Jul 2017 → Oct 2019 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Terminated | No outcome recorded |
| Phase 1/2 | NCT03010358 | Jul 2017 → Apr 2021 | B-cell prolymphocytic leukemia, Richter transformation, anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +4 | Alexey Danilov, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02568683 | Feb → Oct 2016 | non-Hodgkin lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT02343939 | Jul 2015 → Sep 2018 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT02404220 | May 2015 → Nov 2018 | acute lymphoblastic leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT02983617 | Apr 2017 → Feb 2019 | B-cell chronic lymphocytic leukemia | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02701634 | May 2016 → Dec 2017 | chronic graft versus host disease | Gilead Sciences | Terminated | Missed primary |
| Phase 2 | NCT01796470 | Jun 2013 → Jan 2015 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01799889 | Mar 2013 → Sep 2017 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05020665 | Nov 2021 → Mar 2023 | acute myeloid leukemia with mutated NPM1 | Kronos Bio | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-06-03 | Gilead Sciences | Results Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia gilead.com ↗
In this study, single-agent treatment with GS-9973 achieved an overall response rate of 49 percent, with an estimated progression-free survival (PFS) rate at 24 weeks of 70 percent. |
| 2013-12-07 | Gilead Sciences | Results Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia gilead.com ↗
The data show that among patients with chronic lymphocytic leukemia (CLL) who received at least eight weeks of GS-9973 monotherapy, 97 percent (n=28/29) experienced a reduction in lymph node size. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-03 | Gilead Sciences | Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia gilead.com ↗ |
| 2013-12-07 | Gilead Sciences | Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia gilead.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Entospletinib | “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic...” NCT02701634 ↗ |
| Known as | CPD 68 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3265032 ↗ |
| Known as | ENTO | “The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD)...” NCT02701634 ↗ |
| Known as | ENTOSPLETINIB (GS-9973) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3265032 ↗ |
| Known as | GS-9973 | “1600 mg GS-9973 (Formulation 1)” NCT01841489 ↗ |
| Known as | SYK INHIBITOR GS-9973 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3265032 ↗ |
| Action | Inhibit | “Given synergistic preclinical activity with phosphatidylinositol 3-kinase δ and spleen tyrosine kinase inhibition, this phase 2 study evaluated the safety and efficacy of the...” PMID 26968534 ↗ Mar 2016 |
| Modality | Small molecule | — CHEMBL3265032 ↗ |
| Route | Oral | “Entospletinib tablets administered orally twice daily” NCT01796470 ↗ |
| Target | SYK | “Given synergistic preclinical activity with phosphatidylinositol 3-kinase δ and spleen tyrosine kinase inhibition, this phase 2 study evaluated the safety and efficacy of the...” PMID 26968534 ↗ Mar 2016 |